CFTR, formally designated ABCC7, is a member of the ATP-binding cassette transporter superfamily that functions as a cyclic AMP–regulated anion channel, conducting chloride and bicarbonate ions across epithelial membranes. Its opening is gated by phosphorylation and by ATP binding and hydrolysis at two nucleotide-binding domains, an architecture it shares with multidrug-resistance transporters. That ionic flux drags water along with it, keeping airway surface liquid, sweat, pancreatic secretions and other bodily fluids at the correct consistency — which is why mutations in the gene produce the thick, sticky mucus, chronic lung infections and pancreatic insufficiency that define cystic fibrosis, one of the most common life-shortening inherited diseases in populations of European descent. More than 2,000 variants have been described in the gene, of which a smaller subset are confirmed disease-causing. Yet over the past two decades it has become clear that the channel is not confined to classic epithelial barriers; it is also expressed in heart muscle, vascular smooth muscle, immune cells and, crucially, adipocytes. Earlier work had established that downregulation of CFTR reduces lipogenesis — the synthesis and storage of fat — and alters lipid metabolism more broadly. What remained unknown, as the authors state in their abstract, was “the role of CFTR in inflammation regulation in adipose tissue.”

Understanding why that question matters requires a brief tour of what obesity actually does to fat. As adipocytes enlarge under chronic caloric surplus, they become stressed: oxygen delivery lags behind tissue expansion, cells distend mechanically, and some begin to die. The stressed tissue starts secreting chemoattractants such as monocyte chemoattractant protein-1, summoning circulating monocytes that infiltrate the fat and mature into pro-inflammatory macrophages. These macrophages often cluster around dying adipocytes in diagnostic structures known as crown-like structures and flood the tissue with tumour necrosis factor-alpha, interleukin-6 and interleukin-1 beta. The resulting cytokine storm activates intracellular kinases such as JNK and IKKbeta, which interfere with insulin receptor signalling and drive insulin resistance not just locally but systemically, as inflammatory molecules and excess free fatty acids spill into the bloodstream. Meanwhile, healthy fat performs vital endocrine work, secreting the insulin-sensitizing hormone adiponectin and helping to regulate whole-body energy balance through leptin; inflammation degrades that function, suppressing adiponectin and promoting leptin resistance. Scientists have a name for this obesity-triggered inflammation — metaflammation — and it is now considered the pivot on which healthy, expandable fat mass turns into metabolically sick fat mass.

Against that backdrop, the researchers set out to determine whether the channel that keeps mucus thin also keeps fat tissue calm. The team explored the role of CFTR in adipose inflammation and lipid metabolism, together with the underlying mechanism, using both in vivo and in vitro models — manipulating the channel in animal models and in cultured adipose cells and then assessing how lipids accumulated, how adipogenic and lipogenic programs behaved, and how inflammatory signals changed. The study’s central conclusion is distilled in its title: CFTR regulates lipid metabolism by relieving adipose inflammation in obesity. In practical terms, the work suggests that when CFTR is present and functional in fat tissue, it helps ease the inflammatory burden that obesity places on adipose tissue, and that this calming effect is entwined with how fat is synthesised, stored and released. Where the channel is downregulated, the data indicate, the tissue tips toward a state in which lipid handling and inflammation are disturbed together — consistent with the earlier observation that loss of CFTR activity reduces lipogenesis and reshapes lipid metabolism throughout the adipose depot.

Although the complete signalling cascade is still being mapped, the finding slots neatly into converging lines of evidence that ion channels are far more than cellular plumbing. Intracellular chloride and bicarbonate concentrations shape cytosolic pH, and shifts in pH are known to modulate inflammatory transcription factors such as NF-kappaB, the master switch that drives many of the cytokines elevated in obese adipose tissue. CFTR activity also influences calcium handling and endoplasmic reticulum stress, and ER stress in distended adipocytes activates the unfolded protein response, whose IRE1alpha–JNK arm simultaneously impairs insulin signalling and inflames the tissue. The hypertrophic adipocyte, drowning in lipid droplets and starved of oxygen, is precisely the cell in which these stress circuits converge. On the lipid side, the lipogenic program governed by SREBP-1c and its targets — fatty acid synthase and acetyl-CoA carboxylase among them — is itself sensitive to the same stress pathways, which is one reason lipid synthesis and inflammation so often rise and fall together. By implicating a single channel on both sides of that ledger, the study raises the possibility that CFTR acts upstream of the vicious feedback loop that couples fat storage to fat inflammation.

The results also resonate with decades of bedside observations that have never quite fit together. People with cystic fibrosis classically struggle to gain weight, a phenomenon long attributed to pancreatic exocrine insufficiency and the caloric cost of chronic infection. Yet abnormalities in fatty acid profiles and lipid handling have been documented in CF patients even when malabsorption is corrected, hinting that the missing channel itself participates in fat metabolism. And as CFTR modulator drugs have extended survival, clinicians have watched overweight, insulin resistance and cystic fibrosis–related diabetes become growing concerns in a population once defined by wasting. A channel that shapes both lipid synthesis and adipose inflammation offers a coherent framework for these scattered observations: CFTR activity influences whether adipose tissue stores energy quietly or stores it while burning with inflammation, and dialing that activity up or down — by gene, by drug or by disease — moves both dials at once.

There are therapeutic implications on both sides of the equation. CFTR happens to be one of the most successfully druggable ion channels in history: potentiators such as ivacaftor boost the channel’s opening, correctors such as lumacaftor, tezacaftor and elexacaftor rescue misfolded protein and escort it to the cell surface, and the triple-therapy combination built from them has transformed cystic fibrosis from a childhood death sentence into a manageable chronic disease for tens of thousands of patients. The new findings raise the speculative but testable question of whether carefully calibrated potentiation of CFTR in adipose tissue might one day help dampen obesity-linked inflammation and its metabolic consequences. Such a repurposing effort would face real obstacles, including the need for tissue specificity, the channel’s legitimate jobs in airways, sweat glands and pancreas, and the uncertainty of long-term systemic activation. In the other direction, the study suggests that metabolic parameters in CF patients receiving powerful modulators deserve close attention, since their adipose CFTR activity now far exceeds anything their bodies experienced before treatment.

Significant caveats remain, as the authors would be the first to acknowledge. The conclusions rest on in vivo and in vitro models, and laboratory adipose biology does not perfectly recapitulate human fat, which differs markedly between visceral and subcutaneous depots, between sexes and across dietary contexts. Human adipose tissue hosts a far more heterogeneous immune-cell landscape than most animal models capture, and the behavior of macrophages in a dish or in a mouse does not always predict their behavior in human tissue. Translating the finding will require measuring CFTR expression and activity in adipose biopsies across gradients of obesity, insulin sensitivity and inflammation, ideally in longitudinal cohorts, and testing whether pharmacologic modulation of the channel reproduces what the genetic and cellular experiments suggest. It will also matter whether the inflammatory effects of CFTR are direct, acting on the adipocytes themselves, or indirect, mediated through the immune cells that infiltrate the tissue — a distinction that determines which cell type any future therapy would need to reach.

For now, the study’s most important contribution may be conceptual: it welds together two literatures that rarely cite each other. The cystic fibrosis field knows CFTR intimately as a defect-corrected channel whose restoration saves lives; the obesity field has spent two decades cataloguing the molecular choreography of inflamed fat. By showing that the same molecule relieves adipose inflammation in obesity and thereby regulates lipid metabolism, the authors make the case for CFTR as a genuine immunometabolic regulator rather than a curiosity of epithelial physiology. “This study aims to explore the role of CFTR in adipose inflammation and lipid metabolism and the underlying mechanism using both in vivo and in vitro models,” the abstract notes — and the answers now emerging suggest that the fat tissue of the future may be discussed in the same breath as ion channels, chloride gradients and the gene that gave cystic fibrosis its name. As obesity rates continue to climb, an unexpected gatekeeper has entered the field.

The study, freshly published in the International Journal of Obesity in 2025, explores the nuances of inflammatory modulation after bariatric surgery, paying special attention to S100A9’s role within both systemic circulation and platelet function. S100A9, often found operating in tandem with its molecular partner S100A8, forms calprotectin, a heterodimer implicated in the regulation of innate immune responses. Elevated S100A9 has been repeatedly observed in chronic inflammatory conditions, and mounting evidence links heightened expression of this cytokine with obesity-induced cardiovascular pathologies. Platelets, beyond their classic role in hemostasis, act as active participants in inflammation, releasing cytokines that exacerbate vascular injury and atherothrombosis. Observing how bariatric surgery modulates S100A9 levels in platelets may shed light on the surgery’s broader immunometabolic effects.

Cardiovascular diseases remain the leading cause of mortality globally, and obesity contributes significantly to this burden by fostering a pro-inflammatory milieu within the vascular system. The adipose tissue in obese individuals is characterized by increased infiltration of immune cells, secretion of inflammatory cytokines, and dysregulated metabolic pathways—all of which collectively drive endothelial dysfunction and plaque instability. S100A9 serves as a critical signaling molecule within this cascade, amplifying inflammatory responses and recruiting additional immune effectors to sites of vascular injury. It is therefore hypothesized that reducing this cytokine through weight loss interventions could disrupt the progression of obesity-related cardiovascular damage.

Through a comprehensive cohort study design, Ahmed and colleagues recruited individuals undergoing bariatric surgery and monitored their S100A9 levels pre- and post-operatively. Blood samples analyzed for circulating S100A9 concentrations revealed a remarkable decline following substantial weight loss induced by bariatric procedures. More strikingly, assessments of platelet-bound S100A9 demonstrated a parallel reduction, suggesting that bariatric surgery not only attenuates systemic inflammation but also directly affects platelet-mediated inflammatory signaling. These findings underscore the dual role platelets play in cardiovascular health and how surgical weight loss interventions can modulate this axis.

Delving deeper into the molecular biology, S100A9 influences cardiovascular pathology through several intertwined mechanisms. It binds to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE), triggering downstream signaling pathways that enhance cytokine production and oxidative stress within the vascular endothelium. By reducing S100A9 availability, bariatric surgery may blunt these harmful signaling cascades, promoting endothelial repair and improving vascular homeostasis. This discovery offers a compelling mechanistic link between surgical weight loss and improved vascular function that transcends the mere reduction of traditional risk factors like hypertension and dyslipidemia.

Additionally, the study investigated the timeline of S100A9 level changes post-surgery, noting that significant reductions were detectable as early as three months after the procedure. This rapid modulation hints at bariatric surgery’s capacity to swiftly recalibrate inflammatory pathways, potentially providing early cardiovascular protection even before maximal weight loss is achieved. The clinical implications of such a swift response emphasize the importance of considering bariatric surgery as a frontline intervention not only for metabolic health but also for reducing cardiovascular risk in obese patients.

Another layer of complexity emerges when considering the heterogeneous nature of bariatric procedures. Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding may differ in their metabolic and inflammatory outcomes. Although the study primarily focused on Roux-en-Y and sleeve gastrectomy patients, preliminary analyses suggest comparable reductions in circulating and platelet S100A9 across these surgical techniques. However, further investigations are warranted to delineate whether procedural variations influence long-term cardiovascular outcomes via differential inflammatory modulation.

Understanding the interplay between S100A9 and platelet function could also inform the development of novel pharmacological therapies that mimic the anti-inflammatory effects observed with bariatric surgery. Targeting S100A9 or its receptors may provide an alternative or adjunctive strategy to surgical intervention, particularly for patients ineligible or unwilling to undergo bariatric procedures. This therapeutic avenue could revolutionize treatment paradigms by mitigating inflammation-driven cardiovascular damage without requiring invasive surgery.

Moreover, the research highlights the importance of a multidisciplinary approach in managing obesity-related cardiovascular disease, integrating surgical, medical, and immunological perspectives. The findings encourage clinicians to monitor inflammatory biomarkers like S100A9 alongside conventional metabolic parameters when evaluating patient progress post-bariatric surgery. Such biomarker-guided assessments could optimize personalized care by identifying patients who are more likely to benefit from specific interventions or require additional therapies.

Importantly, the study also acknowledges limitations, including the relatively small sample size and the need for long-term follow-up to assess sustained effects on cardiovascular events. Future research should aim to validate these findings in larger, diverse populations and explore the direct impact of reduced S100A9 on clinical cardiovascular endpoints. Integrating advanced omics technologies may also deepen insight into the global metabolic reprogramming induced by bariatric surgery.

The implications of these findings extend beyond cardiovascular disease, as chronic inflammation is a hallmark of multiple obesity-related conditions such as type 2 diabetes, non-alcoholic fatty liver disease, and certain cancers. Given S100A9’s central role in systemic inflammation, its modulation by bariatric surgery may also confer protective effects across a wide spectrum of diseases, highlighting the systemic benefits of surgical weight loss.

In summary, the work by Ahmed et al. represents a significant leap forward in elucidating the molecular underpinnings of bariatric surgery’s cardiovascular benefits. By characterizing how circulating and platelet-associated S100A9 levels are reduced following surgical intervention, the study provides compelling evidence that attenuation of inflammation plays a pivotal role in the improved cardiovascular profile observed among treated patients. This enhanced understanding opens new avenues for targeted therapeutic innovation aimed at breaking the vicious cycle of obesity-induced inflammation and vascular damage.

As obesity prevalence continues to rise worldwide, novel insights into immune-metabolic crosstalk such as the role of S100A9 become increasingly vital for shaping effective treatment strategies. The demonstrated rapid decrease in a pro-inflammatory cytokine coupled with improved platelet function highlights bariatric surgery’s unique ability to reset inflammatory homeostasis. For clinicians, researchers, and patients alike, this represents a beacon of hope—a tangible molecular explanation for improved cardiovascular longevity and quality of life in the face of a global obesity epidemic.

Forthcoming studies will hopefully expand on these preliminary but critical findings, establishing robust clinical guidelines and pushing forward the frontier of precision medicine. With inflammation as a modifiable target and bariatric surgery as a powerful therapeutic tool, the prospects for mitigating obesity-related cardiovascular morbidity have never looked more promising. The dialogue between immune cells, platelets, and vascular tissue is intricate yet malleable, and harnessing this complexity through surgical and pharmacological innovations may unlock a new era of cardiovascular risk management in obesity.

Subject of Research: The effect of bariatric surgery on circulating and platelet-associated S100A9 levels in individuals with obesity and its implications for cardiovascular inflammation and risk.

Article Title: Characterizing the effect of bariatric surgery on circulating S100A9.

Article References:
Ahmed, H., Guzman, A., Zhang, R. et al. Characterizing the effect of bariatric surgery on circulating S100A9. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01868-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01868-5